CLN-978

Phase 1Small molecule

CCullinan Therapeutics Inc.

CLN-978 is one of 117 small molecule programs targeting Systemic Lupus Erythematosus. It is currently in Phase 1.

Indications

Total Trials

Active Trials

116

Competitors

Pipeline

Status by Indication[3][1]

Indication

Systemic Lupus ErythematosusActive, not recruiting

LymphomaActive, not recruiting

Rheumatoid ArthritisActive, not recruiting

Systemic Lupus ErythematosusPhase 1

Active, not recruiting

LymphomaPhase 1

Active, not recruiting

Rheumatoid ArthritisPhase 1

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Blenoxane

SSequus Pharmaceuticals

Preclinical

25 2

Velban

EEastern Cooperative Oncology Group

Preclinical

15 3

Zofran

Novartis

Preclinical

2 4

Tafasitamab

Incyte

Preclinical

7 5

Nuvigil

NNuvo Research GmbH

Preclinical

1 6

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—7

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—8

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Systemic Therapy

1 10

CLN-978

CCullinan Therapeutics Inc.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Active, not recruiting

Lymphoma

NCT05879744

Q4 2027

Phase 1Recruiting

Systemic Lupus Erythematosus

NCT06613360

Q4 2028

Phase 1Recruiting

Rheumatoid Arthritis

NCT06994143

Q1 2029

Phase 1Recruiting

T Cell

NCT07041099

Clinical

Trials by Indication[1]

Lymphoma1 trial

A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL)

Active, not recruiting·CCullinan Therapeutics Inc.·Phase 1·NCT05879744·90 enrolled

Systemic Lupus Erythematosus1 trial

A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus

Recruiting·CCullinan Therapeutics Inc.·Phase 1·NCT06613360·24 enrolled

T Cell1 trial

A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease

Recruiting·CCullinan Therapeutics Inc.·Phase 1·NCT07041099·36 enrolled

Rheumatoid Arthritis1 trial

A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Rheumatoid Arthritis

Recruiting·CCullinan Therapeutics Inc.·Phase 1·NCT06994143·37 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for CLN-978. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CLN-978 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CLN-978. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Cullinan Therapeutics Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: CCullinan Therapeutics Inc.

CLN-978

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q4 2027

Q4 2028

Q1 2029

Trials by Indication[1]

Lymphoma1 trial

Systemic Lupus Erythematosus1 trial

T Cell1 trial

Rheumatoid Arthritis1 trial

References

Drug Info

Quick Facts

Related News